PPARA and fatty liver disease: AMPK activation induces peroxisome proliferator-activated-receptor-α (PPAR-α) signalling, which in turn induces anti-inflammatory signalling, reduces adipose-tissue-derived factors that could stimulate steatosis [18], and inhibits SREBP activity, thereby reducing the development of hepatic steatosis [47].